drug
secukinumab
Marketedupdated 5mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying secukinumab
- phase1Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
- phase4Secukinumab Open Label Roll-over Extension Protocol
- phase4Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
- —Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
- phase3Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
- phase3Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
- phase4Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
- —Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
News(5)
- ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’ai3Bio has emerged from stealth with $48 million in funding and a buzzing platform for targeting T cells in autoimmune disease.fiercebiotech · 10d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 10d ago
- Novartis’ board faces investor scrutiny after M&A misfires and R&D flopsBack-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.biospace · 27d ago
- Novartis climbs on upbeat drug sales as key readouts loomA return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.biopharma_dive · 2mo ago
- Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsNovartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma's second quarter earnings call—though major pickups aren’t completely o…biospace · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that